Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

A Review on Efficacy and Safety of SGLT2 Inhibitors as Add-on Therapy with Metformin

Metformin에 추가로 병용되는 SGLT2 inhibitors의 효능과 안전성에 관한 고찰

  • Received : 2018.08.08
  • Accepted : 2018.09.20
  • Published : 2018.09.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The new type of diabetes treatment, SGLT2 inhibitors, has been approved for monotherapy and combination therapy, but medical insurance is only allowed in combination therapy with metformin, which is the first choice for type 2 diabetes treatment. Methods: The SGLT2 inhibitors prescribed in Korea are dapagliflozin, empagliflozin and ipragliflozin. A review was conducted using Pubmed to evaluate efficacy and safety for these medications with metformin combination therapy. 10 studies were selected by searching for keywords and related references and were reviewed in full. The mechanism of action, pharmacokinetics, and the economics of treatment with SGLT2 inhibitors were examined. Results: SGLT2 inhibitors had moderate glycemic control when added to the treatment of patients with type 2 diabetes who were not being regulated by metformin monotherapy. They also showed positive effects such as weight loss, as well as the lowering of blood pressure. Hypotension and serious side effects were relatively low. However, the risk of genital infection was increased. Conclusion: The SGLT2 inhibitors are a new class of drugs that promote glucose excretion in the urine. They are a good choice for combination therapy with metformin for the treatment of type 2 diabetes, with weight loss and very low risk of serious side effects.

Keywords

References

  1. Korean statistical Information Service. Available from http://kosis.kr/eng/search/search01_List.jsp. Accessed July 12, 2018.
  2. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care 2018; 41(Supplement 1):S73-S85. https://doi.org/10.2337/dc18-S008
  3. U.S. Food and Drug Administration. Canagliflozin prescribing information. Available from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204042. Accessed July 12, 2018.
  4. European Medicines agency. Find medicine. Available from http://www.ema.europa.eu/ema/. Accessed August 7, 2018.
  5. U.S. Food and Drug Administration. Jardiance prescribing information. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204629s016lbl.pdf. Accessed July 12, 2018.
  6. Nainggolan L. Ipragliflozin (Suglat) First of new diabetes drug class in Japan. Available from https://www.medscape.com/viewarticle/819447. Accessed July 12, 2018.
  7. Ministry of Food and Drug Safety. Online medicine library. Available from http://drug.mfds.go.kr/html/index.jsp. Accessed August 20, 2017.
  8. Kawalec P, Mikrut A, Lopuch S. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Res Rev 2014;30(4):269-83. https://doi.org/10.1002/dmrr.2494
  9. Health insurance review & assessment service. Available from http://www.hira.or.kr. Accessed August 4, 2018.
  10. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Invest 2014;5:265-75. https://doi.org/10.1111/jdi.12214
  11. Monica Reddy RP, Inzucchi SE. SGLT2 inhibitors in the management of type 2 diabetes. Endocrine 2016;53(2):364-72. https://doi.org/10.1007/s12020-016-0943-4
  12. U.S. Food and Drug Administration. Drugs@FDA. Farxiga prescribing information. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202293s012lbl.pdf. Accessed July 12, 2018.
  13. Kasichayanula S, Liu X, Zhang W, et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes Metab 2011;13(8):770-3. https://doi.org/10.1111/j.1463-1326.2011.01397.x
  14. Ministry of Food and Drug Safety. Product information. Available from https://ezdrug.mfds.go.kr/#!CCBAA03F010. Accessed July 1, 2018.
  15. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, doubleblind, active-controlled noninferiority trial. Diabetes Care 2011;34(9): 2015-22. https://doi.org/10.2337/dc11-0606
  16. Nauck MA, Del Prato S, Duran-Garcia S, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab 2014;16(11):1111-20. https://doi.org/10.1111/dom.12327
  17. Del Prato S, Nauck M, Duran-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 2015;17(6):581-90. https://doi.org/10.1111/dom.12459
  18. Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013;11:43. https://doi.org/10.1186/1741-7015-11-43
  19. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9733):2223-33. https://doi.org/10.1016/S0140-6736(10)60407-2
  20. Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014;16(2):159-69. https://doi.org/10.1111/dom.12189
  21. Zhang Q, Dou J, Lu J. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses. Diabetes Res Clin Pract 2014;105(3):313-21. https://doi.org/10.1016/j.diabres.2014.06.006
  22. Araki E, Tanizawa Y, Tanaka Y, et al. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2015;17(7):665-74. https://doi.org/10.1111/dom.12464
  23. Dziuba J, Alperin P, Racketa J, et al. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab 2014;16(7):628-35. https://doi.org/10.1111/dom.12261
  24. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 Diabetes. N Engl J Med 2015;373 (22):2117-28. https://doi.org/10.1056/NEJMoa1504720
  25. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015;12(2):90-100. https://doi.org/10.1177/1479164114559852
  26. Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 Inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG OUTCOME Study. Diabetes Care 2016;39(5):717-25. https://doi.org/10.2337/dc16-0041
  27. Rizzo M, Al-Busaidi N, Rizvi AA. Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives. Expert Opin Pharmacother 2015;16(3):281-4. https://doi.org/10.1517/14656566.2015.981528
  28. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16(5):457-66. https://doi.org/10.1111/dom.12244
  29. Lin HW, Tseng CH. A Review on the relationship between SGLT2 Inhibitors and cancer. Int J Endocrinol 2014;2014:719578.
  30. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res 2015;12(2):78-89. https://doi.org/10.1177/1479164114561992
  31. Ndefo UA, Anidiobi NO, Basheer E, et al. Empagliflozin (Jardiance): A novel SGLT2 Inhibitor for the treatment of type-2 diabetes. Pharmacy and Therapeutics 2015;40(6): 64-8.
  32. Veltkamp SA, Kadokura T, Krauwinkel WJ, et al. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose cotransporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig 2011;31(12):839-51. https://doi.org/10.1007/BF03256922
  33. U.S. Food and Drug Administration. Glucophage prescribing information. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020357s034,021202s018lbl.pdf. Accessed July 12, 2018.
  34. Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013;15(12):1154-60. https://doi.org/10.1111/dom.12185
  35. Haring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as addon to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37(6):1650-9. https://doi.org/10.2337/dc13-2105
  36. Wilding JP, Ferrannini E, Fonseca VA, et al. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab 2013;15(5):403- 9. https://doi.org/10.1111/dom.12038
  37. Kashiwagi A, Kazuta K, Goto K, et al. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 dia- betes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2015;17(3):304-8. https://doi.org/10.1111/dom.12331